Refine
Year of publication
- 2021 (1)
Document Type
- Doctoral Thesis (1)
Language
- English (1)
Has Fulltext
- yes (1)
Is part of the Bibliography
- no (1)
Keywords
Institute
Due to demographic changes, medical and nursing care in Germany faces new challenges. Combined with the aging of the population, an increase in age-associated diseases, including dementia, is to be expected. In addition to the increase in the number of persons with certain age-specific diseases, the aging of the German population also results in an increase in the number of persons with multiple diseases. The coexistence of dementia and comorbidity in people with dementia creates complex challenges for ambulatory and clinical care. The existence of comorbidity also leads to significantly higher medical costs.
Implementing new collaborative care programs and redistributing the responsibilities among outpatient care providers in the ambulatory care of patients may be one approach to ensure and improve the life and care situation of people with dementia. Collaborative Dementia Care Management, with the concept of support of general practitioners by specific qualified nurses demonstrated an adequate and effective approach for the compensation of supply deficits of PwD in the primary care sector. The aim of the dissertation is the health economic analysis of comorbidities in dementia and the evaluated Dementia Care Management of the DelpHi-MV study as an innovative approach for care and treatment of comorbidities in people with dementia. It is assumed that the cost of care for PwD varies depending on comorbidity and socio-demographic and clinical characteristics. Therefore, the health care costs of people with dementia are calculated and the association between these care costs and comorbidity and socio-demographic and clinical factors of PwD was analyzed. In addition, we aimed to detect important subgroups (e.g. PwD with low, high or very high comorbidity) who benefit most from the DCM intervention and for whom a significant effect on costs, Quality-adjusted Life Years (QALY) and on the individual cost-effectiveness could be achieved, considering different sociodemographic and clinical characteristics like comorbidity.
In the sample of PwD comorbidity was highly prevalent. 47% of PwD had a very high, 37% a high and only 16% a low comorbidity in addition to dementia. The most prevalent co-existing comorbidity were diabetes mellitus (42%), peripheral vascular disease (28%) and cerebrovascular disease (25%). Total costs significantly increased by 528 € (SE=214, CI 95%=109-947, p=0.014) with each further comorbidity, especially due to significantly higher cost for medication and medical aids. Compared with a low comorbidity, a very high comorbidity was significantly associated with 818 € (SE=168, CI 95%= 489-1147, p<0.001) higher medication costs and 336 € (SE=161, CI 95%=20-652, p=0.037) higher cost for medical aids. There was no significant association between a higher comorbidity and cost for formal care services. The probability of DCM being cost-effective at a willingness-to-pay of 40,000€/QALY was higher especially in PwD having a high comorbidity (96% vs. 26% for patients with a low comorbidity), in females (96% vs. 16% for males), in those living alone (96% vs. 26% for those living not alone) and in those being moderately to severely cognitively (100% vs. 3% for patients without cognitive impairment) and functionally impaired (97% vs. 16% for patients without functional impairment).
Comorbidity in PwD represents a substantial financial burden on healthcare payer’s and is a challenge for patients, healthcare providers and the health system. Innovative approaches are needed to achieve a patient-oriented management of treatment and care in comorbid PwD to reduce long-term costs. Collaborative dementia care management is one approach to solve these problems in dementia care. Thereby, patients characteristics significantly affect the cost-effectiveness of collaborative care. Female patients, patients living alone, and those with a high comorbidity as well as those being moderately cognitively and functionally impaired benefit most from DCM. For those subgroups of patients, healthcare payers could gain the highest cost savings and the highest effects on QALYs when the DCM approach will be implemented.